|
|
|
| The Application of Immuno-Histochemistry, Dual-Color Silver-Enhanced Insitu Hybridization and Fluorescence Insitu Hybridization to Detect the HER-2 Gene Status in Breast Cancer |
| LIU Jiying, CHEN Mingguang, HAN Mingqi, et al |
| Nanping First Hospital, Fujian Nanping 353000, China |
|
|
|
|
Abstract Objective: To compare the effects of immuno-histochemistry (IHC), dual-color silver-enhanced insitu hybridization (DISH) and fluorescence insitu hybridization (FISH) on the status of breast cancer HER-2 gene. Methods: Retrospective study was conducted on 180 cases of unilateral breast cancer patients admitted to our hospital from January 2017 to December 2019, all of whom were female . Tissue specimens were collected and examined for HER-2 by IHC, DISH and FISH. Results: Results of HER-2 gene in 180 patients: IHC test showed negative expression of HER-2 in 118 patients and positive expression of HER-2in 49 patients. DISH detection of HER-2 gene amplification was performed in 56 cases, 107 cases without amplification and 17 cases with uncertainty. FISH detected 54 cases of HER-2 amplification, 107 cases without amplification, and 19 cases with uncertainty. Comparison of different detection Methods: the Kappa value of HER-2 gene detected by DISH and IHC was 0.788, showing good consistency; The Kappa value of HER-2 gene examined by FISH and IHC was 0.784, wIHCh was highly consistent; The Kappa value of HER-2 gene detected by DISH and FISH was 0.939, indicating a high consistency. Conclusion: IHC, DISH and FISH can evaluate the her-2 gene status of breast cancer patients, and IHC can be used as a screening method. If medical resources permit, treatment plans should be made based on DISH test results.
|
|
|
|
|
|
[1] Hou F, Shi D B, Chen Y Q, et al. Human epidermal growth factor receptor-2 promotes invasion and metastasis in gastric cancer by activating mitogen-activated protein kinase signaling[J]. Applied Immunohistochemistry & Molecular Morphology, 2019, 27(7):529~534..
[2] Kim H, Seo S H, Kim K H, et al. Prognostic significance of Human epidermal growth factor receptor-2 expression in patients with resectable gastric adenocarcinoma[J]. World Journal of Surgical Oncology, 2019, 17(1):1~9.
[3] Bogdanovska Todorovska M, Petrushevska G, Janevska V, et al. Standardization and optimization of fluorescence in situ hybridization (FISH) for HER-2 assessment in breast cancer: A single center experience[J]. Bosnian Journal of Basic Medical Sciences, 2018, 18(2):132~140.
[4] Wolff AC, Hammond ME, Hicks DG. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: american society of cinical oncology/college of american pathologists clinical practice guideline update[J]. archives of pathology & laboratory medicine, 2013, 31(31):3997~4013.
[5] Q, Y, Liu,et al. Clinicopathologic and molecular subtyping analysis of occult breast cancer.[J]. Chinese Journal of Pathology, 2018, 47(8):633~634.
[6] 董兵斌,刘伊铖,李铨,等.HER-2/CEP17信号比与乳腺癌新辅助化疗后病理完全缓解的相关性研究[J].中国肿瘤临床,2018,45(16):832~837
[7] Koji Takada, Shinichiro Kashiwagi, Wataru Goto,et al. Analysis of HER family (HER1-4) expression as a biomarker in combination therapy with pertuzumab, trastuzumab and docetaxel for advanced HER2-positive breast cancer[J]. anticancer research, 2018, 38(4):2285~2294.
[8] 吴蔼林,陈静瑶,李飞,等.HER-2阳性乳腺癌生物学特征与分子靶向治疗研究进展[J].中华保健医学杂志,2018,20(2):169~170,176.
[9] Fouzia, Lateef, Saba,et al. Her-2/neu oncogene amplification by fluorescence in situ hybridization and protein overexpression on immunohistochemistry in breast cancer.[J]. Journal of the College of Physicians & Surgeons Pakistan Jcpsp, 2018, 28(8):581~585. |
|
|
|
2020, Vol. 26 
